Navigation Links
Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Date:2/5/2008

RICHMOND, Va., Feb. 5 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) CEO Geoffrey Allan issued the following statement today following the White House FY09 Budget and Food and Drug Administration statements on developing an approval pathway for follow-on biologics:

"Insmed is very pleased to see that the White House recognizes the importance of establishing a follow-on biologics approval pathway to deliver safe and more affordable medicines to Americans.

"We are also pleased by news of the Food and Drug Administration's preparation of a proposal to assist the Congress in moving forward with legislation to establish an approval pathway for follow-on biologics.

"We hope that the attention this important issue has received from both the White House and FDA will move Congress to adopt follow-on biologics legislation so patients can receive safe and affordable access to generic versions of these life-saving biotech drugs."

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. Insmed has a state-of-the- art, FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a Corporate office in Richmond, Virginia. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. Insmed to Appeal Delisting Notification From Nasdaq
3. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
4. Insmed Appoints Dennis M. Lanfear to Board Of Directors
5. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
6. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. CCPM Issues Statement on FDAs GIVE Initiative
9. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
10. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
11. HHS Issues First Department-Wide Report on Personalized Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... NC (PRWEB) March 06, 2015 ... innovative specialty CRO focused on specimen management and ... closed. , “Global Specimen Solutions, Inc. is excited ... management with investment that will further enhance our ... first-to-market services supporting specimen research. GSS has proved ...
(Date:3/6/2015)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... marketed as XIAFLEX ® (collagenase clostridium histolyticum or ... EU, announced today that it will host a conference ... on Friday, March 13, 2015 to report its fourth ... a corporate update. In order to ...
(Date:3/6/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... Poyhonen , the Company,s President and Chief Executive Officer, ... Chief Financial Officer, will present an overview of Senomyx,s ... at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Transparency Market Research ... and Other Crops - Global Industry Analysis, Size, Share, Growth, ... the global isoxaflutole market was valued at US$ 116.3 Mn ... by 2020, expanding at a CAGR of 5.1% from 2014 ... isoxaflutole stood at 2,569.5 kilo tons in 2013. , Isoxaflutole ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3
... WALTHAM, Mass., Dec. 11, 2011 Syndax Pharmaceuticals, ... a multicenter, phase 2 study, demonstrated entinostat, a novel, ... showed activity as a single agent in patients with ... being presented today, December 11, from 6:00 to 8:00 ...
... ANGELES, Dec. 9, 2011  Puma Biotechnology, Inc., a ... ongoing Phase II clinical trials of Puma,s investigational ... CTRC-AACR San Antonio Breast Cancer Symposium that is ... presentations are further detailed below: ...
... a heart surgeon at Gundersen Lutheran Health System ... an exciting technique, called minimally invasive coronary surgery ... very small three-inch cut is made between the ribs instead of ... with traditional open heart surgery. This means less pain and ...
Cached Biology Technology:Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 2Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 4Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 6Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... beetles and only two species of the tuatara, a reptile ... Crocodiles and alligators, while nearly 250 million years old, have ... including mammals and many species of birds and fish ... Scientists have often posited that because some ...
... of America (ESA) is pleased to announce the selection of ... Membership acknowledges those who have served ESA for at least ... Society that has reached an extraordinary level. Candidates for this ... voted on by the ESA membership. All four will be ...
... largely restricted to the eastern edge of the New England Tableland, and ... this flowering plant, until now classified as a variety of the Hairpin ... a distinct species. The study was published in the open access journal ... family of flowering plants that includes the Banksia and ...
Cached Biology News:Why are there so many species of beetles and so few crocodiles? 2Why are there so many species of beetles and so few crocodiles? 3Entomological Society of America names 2012 Honorary Members 2Entomological Society of America names 2012 Honorary Members 3Entomological Society of America names 2012 Honorary Members 4Botany student proves 'New England Banksia' a distinct species 2
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
... The biolistic PDS-1000 He system ... gas to accelerate micron-size nucleic acid-coated ... necessary to transfect cells, tissues, or ... the cell surface. The system includes ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... The MyCycler thermal cycler system is ... applications. This system includes the MyCycler personal ... module for use with 0.2 ml tubes ... options, and both algorithm and block modes ...
Biology Products: